| Bioactivity | HYDAMTIQ is a PARP-1/2 inhibitor (IC50: 29-38 nM) with anticancer, anti-inflammatory, and ischemic protective effects. HYDAMTIQ inhibits pulmonary PARP activity, is effective against allergen-induced cough and dyspnea, and inhibits bronchial hyperresponsiveness to methacholine. HYDAMTIQ has broad-spectrum tumor suppressor effects, including ovarian and breast cancers, prostate and pancreatic tumors, and glioblastoma multiforme. HYDAMTIQ has demonstrated in vivo efficacy in animal models of cerebral ischemia, asthma, cancer, and more[1]. |
| Target | PARP-1/2 |
| Name | HYDAMTIQ |
| CAS | 1201832-32-7 |
| Formula | C14H14N2O2S |
| Molar Mass | 274.34 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Filipponi P et al. Continuous Flow Synthesis of the PARP-1/2 Inhibitor HYDAMTIQ: Synthetic Strategy, Optimization, and Green Metrics Evaluation[J]. Organic Process Research & Development, 2023. |
HYDAMTIQ
CAS: 1201832-32-7 F: C14H14N2O2S W: 274.34
HYDAMTIQ is a PARP-1/2 inhibitor (IC50: 29-38 nM) with anticancer, anti-inflammatory, and ischemic protective effects. H
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.